Biolegend, 100321, Alexa Fluor® 488 anti-mouse CD3ε Antibody
100microg
Catalog Number: 100321
Send an RFQ.
Category
Loading…
| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Armenian Hamster |
| Immunogen | H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37 |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions. |
| Concentration | 0.5 mg/ml |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses |
| Excitation Laser |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Blue Laser (488 nm) |
| Application Notes | Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32, and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). |
|---|
| Application References(PubMed link indicates BioLegend citation) | Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block) Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ) Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB) Payer E, et al. 1991. J. Immunol. 146:2536. (IF) Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD) Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ) Henrickson M, et al. 1995. Transplantation 60:828. (Deplete) Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete) Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete) Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block) Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ) Ko SY, et al. 2005. J. Immunol. 175:3309. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F) Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F) Wang W, et al. 2007. J. Immunol. 178:4885. (Activ) Xiao S, et al. 2007. J. Exp. Med. 204:1691. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Kenna TJ, et al. 2008. Blood 111:2091. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed Schulteis RD, et al. 2008. Blood 295:G273. PubMed Qi Q, et al. 2009. Blood 114:564. PubMed Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed Yan J, et al. 2014. Vaccine. 32:2833. PubMed Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed Shi YF, et al. 1991. J Immunol. 146:3340. (Apop) |
|---|
| Product Citations | Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed Shigematsu Y, et al. 2013. Cancer Lett . 340:141. PubMed Bhattacharya Y 2014. J Exp Med. 211:841. PubMed Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed Baranek T, et al. 2020. Cell Reports. 32(10):108116. PubMed del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed Onishi S, et al. 2015. PLoS One. 10:126564. PubMed Tian D, et al. 2020. FASEB J. 34:3367. PubMed He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed Chen C, et al. 2019. Cell Rep. 29:4200. PubMed Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed Bambouskova M, et al. 2021. Cell Reports. 34(10):108756. PubMed Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed Oka Y, et al. 2020. Sci Adv. 6:. PubMed Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed Hu M, et al. 2020. Cancer Immunol Res. 8:1150. PubMed de Picciotto S, et al. 2022. Nat Commun. 13:3866. PubMed Miyajima M,et al. 2017. Nat Immunol.. 10.1038/ni.3867. PubMed Wu R, et al. 2020. J Immunother Cancer. 8:00. PubMed Ajith A, et al. 2019. FASEB J. 33:5220. PubMed Uotila LM, et al. 2017. J Immunol. 199:3644. PubMed |
|---|
| RRID | AB_389300 (BioLegend Cat. No. 100321) |
|---|
| Structure | Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD |
|---|
| Distribution | Thymocytes (differentiation dependent), mature T cells, NK-T cells |
|---|
| Function | TCR signal transduction, T cell activation, antigen recognition |
|---|
| Ligand/Receptor | Peptide antigen/MHC-complex |
|---|
| Cell Type | NKT cells, T cells, Thymocytes, Tregs |
|---|
| Biology Area | Immunology |
|---|
| Molecular Family | CD Molecules, TCRs |
|---|
| Antigen References | 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263. |
|---|
| Gene ID | 12501 |
|---|
| UniProt | View information about CD3epsilon on UniProt.org |
|---|
| Clone | 145-2C11 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | CD3ε, T3, CD3 |
|---|
| Isotype | Armenian Hamster IgG |
|---|
